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Abstract
Background: The lack of a suitable animal model to study viral and immunological mechanisms of human dengue disease
has been a deterrent to dengue research.
Methodology/Principal Findings: We sought to establish an animal model for dengue virus (DENV) infection and immunity
using non-obese diabetic/severe combined immunodeficiency interleukin-2 receptor c-chain knockout (NOD-scid IL2rc
null)
mice engrafted with human hematopoietic stem cells. Human CD45
+ cells in the bone marrow of engrafted mice were
susceptible to in vitro infection using low passage clinical and established strains of DENV. Engrafted mice were infected
with DENV type 2 by different routes and at multiple time points post infection, we detected DENV antigen and RNA in the
sera, bone marrow, spleen and liver of infected engrafted mice. Anti-dengue IgM antibodies directed against the envelope
protein of DENV peaked in the sera of mice at 1 week post infection. Human T cells that developed following engraftment
of HLA-A2 transgenic NOD-scid IL2rc
null mice with HLA-A2
+ human cord blood hematopoietic stem cells, were able to
secrete IFN-c, IL-2 and TNF-a in response to stimulation with three previously identified A2 restricted dengue peptides NS4b
2353(111–119), NS4b 2423(181–189), and NS4a 2148(56–64).
Conclusions/Significance: This is the first study to demonstrate infection of human cells and functional DENV-specific T cell
responses in DENV-infected humanized mice. Overall, these mice should be a valuable tool to study the role of prior
immunity on subsequent DENV infections.
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Introduction
Dengue viruses (DENV) are small enveloped RNA viruses with
a single-stranded positive sense genome in the family Flaviviridae.
Of the flaviviruses, DENV have the most significant impact on
morbidity and mortality worldwide with over 100 million
infections estimated annually [1]. In most cases, infection is either
minimally symptomatic or results in an uncomplicated, though
sometimes severe, acute febrile illness (dengue fever, DF). In a
small percentage of cases, however, individuals develop a severe
capillary leakage syndrome, dengue hemorrhagic fever (DHF),
which can be life-threatening [2].
Studies on humans infected with DENV provide strong evidence
for an immunologic basis for the pathogenesis of DHF. DHF is
strongly associated with a secondary DENV infection, i.e. infection
in individuals with pre-existing DENV-specific antibodies and
memory T cells from an earlier infection with a different DENV
serotype [3–5]. Therefore, experimental manipulation of in vivo
immune responses to DENV would be a desirable approach to
explore the role of prior immunity on subsequent DENV infection
and to test the potential for candidate vaccines and therapeutics.
Subcutaneous injection of DENV into non-human primates
results in productive infection with animals developing DENV-
specific antibody and memory T cell responses [6,7] but no clinical
disease. Several murine models for DENV-induced disease have
been reported that have been useful in dissecting some key aspects
of disease pathogenesis [8–14]. However, major limitations of
these models include the use of very high input doses of virus,
routes of inoculation that do not mimic natural infection and the
use of mouse-adapted strains of virus.
Data from several laboratories indicate that human cells
represent the most susceptible cells to DENV infection. Previous
attempts at engrafting immunodeficient mice with human cells as
targets for DENV infection have yielded limited success partly
becauseoflowlevelsofhumanengraftment[15].BenteandMotoet
al immunized engrafted NOD-scid mice with clinical strains of
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7251DENV-2 [16,17]. Infected engrafted mice developed clinical signs
of dengue disease including thrombocytopenia and erythema
compared to infected non-engrafted mice and uninfected engrafted
mice. Kuruvilla et al used humanized BALB/c-RAG2
2/2cc
2/2
mice (RAG hu) and demonstrated that these mice developed
dengue-specific IgM and IgG antibodies several weeks after
infection [18]. The data by these two groups are promising,
however human T cell responses in engrafted mice were not
examined in either of these studies.
Novel mouse models have recently been described that permit
long term multi-lineage human hematopoiesis and immune
response [19–21]. We utilized NOD-scid IL2rc
null mice, considered
the ‘‘gold standard’’ strain for human hematolymphoid develop-
ment to determine whether humanized mice will support
productive infection with DENV [20,22–24]. We identified
human cells that were targets of in vitro and in vivo infection
with DENV. Human T cells from infected engrafted mice
produced IFN-c, TNF-a and IL-2 in response to stimulation with
three HLA A2 restricted dengue virus-specific peptides. These
mice also developed IgM antibodies directed against the DENV
envelope protein. Our results are a promising first step towards
developing a small animal model with a functional human
adaptive immune system to study human dengue virus induced
immunity and disease.
Results
Human hematopoiesis in NOD-scid IL2rc
null mice
T cell-depleted human cord blood cells containing 3610
4
CD34
+ cells were transplanted into NOD-scid IL2rc
null mice as
described in Materials and Methods. Approximately 3 months
later, peripheral blood, spleen and bone marrow of engrafted
mice were assessed for human hematopoiesis by using an
antibody directed against the pan leukocyte marker human
CD45 (Fig. 1). In accordance with published data [24], we
obtained high levels of human hematolymphoid cell engraftment
in these mice: 45–75% of cells i nt h el y m p h o c y t eg a t e( a s
determined by forward and light scatter) of PBMC (n=26), 40–
68% in the spleen (n=31) and 40–60% in the bone marrow
(n=31), were hCD45
+ suggesting that NOD-scid IL2rc
null mice
support human hematopoiesis (Fig. 1A). Multilineage human
hematopoiesis was assessed in the bone marrow (Fig. 1B) and
spleen (Fig. 1C) of engrafted mice using antibodies against
human CD19
+ Bc e l l s ,C D 1 1 c
+ dendritic cells, CD3
+ Tc e l l sa n d
CD16
+ NK cells. While the frequencies of engrafted human
subsets varied between mice all the above subtypes were
consistently found in engrafted mice. The data demonstrate that
engrafted NOD-scid IL2rc
null mice develop all components of a
functional human adaptive immune system.
Figure 1. Human hematopoiesis in organs of engrafted NOD-scid IL2rc
null mice. (A) Approximately 3 months after engraftment of NOD-scid
IL2rc
null mice with human T cell-depleted umbilical cord blood cells, reconstitution was assessed in target organs using flow cytometry. Values on the
Y-axis represent frequencies of hCD45
+ and mCD45
+ cells within the mononuclear cell gates in the PBMC (n=26), spleen (n=31) and all cells in the
bone marrow (n=31). Error bars represent standard deviation from the mean value. (B,C) Representative flow cytometry plots demonstrating human
hematopoiesis in the bone marrow (B) and spleen (C) of an engrafted mouse.
doi:10.1371/journal.pone.0007251.g001
Humanized Mice and Dengue
PLoS ONE | www.plosone.org 2 October 2009 | Volume 4 | Issue 10 | e7251Human cells in engrafted NOD-scid IL2rc
null mice support
dengue infection
We first wanted to determine whether human CD45
+ cells
derived from human stem cell engrafted NOD-scid IL2rc
null mice
could be infected with DENV. We therefore infected bone marrow
cells with clinical and laboratory strains of DENV-type 2 (DENV-
2). Initial gating strategy based on forward and side scatter was
used to identify cells with high side scatter (gate 1) and cells with
low side scatter (gate 2) (Fig. 2A). As shown in Fig. 2B, forty-eight
hrs after in vitro infection, approximately 10–15% of human
CD45
+ cells in gate 1 stained positive with the DENV-specific
monoclonal antibody 3H5, following infection with DENV-2
NGC strain. In comparison, infection with a low passage Thai
isolate or the DENV-2 strain 16681 yielded lower frequencies
(0.5–6%) of DENV antigen-positive cells. Cells in gate 2 showed
low to absent staining with 3H5 (data not shown). In subsequent
experiments using bone marrows from different engrafted mice,
we have detected a wide range of infectivity (0.5–15%) following in
vitro infection with DENV-2 NGC (Fig. 2C).
Infected bone marrow cells derived from engrafted NOD-scid
IL2rc
null mice were also assessed for dengue antigen expression by
immunoperoxidase staining. We could detect DENV antigen in
infected bone marrow cells (Fig. 2D) while uninfected bone
marrow cells had no antigen-positive cells (Fig. 2E). The specificity
of staining was confirmed using the 3H5 antibody on persistently
infected Raji cells (Fig. 2F) and uninfected Raji cells (Fig. 2G).
Together with the flow cytometry data, our results demonstrate
that strains of DENV-2 that we tested differentially infect human
cells in the bone marrow of engrafted mice.
In vivo infection with dengue virus
Engrafted mice were next infected with 10
6 PFU DENV-2 NGC
by either the i.p. or s.c. route, the latter of which more closely
mimics the natural route of infection. We monitored infected and
control mice for signs of illness. Many infected mice experienced
significant weight loss (greater than 25% of their initial body
weight), had ruffled fur, and showed a hunched posture (data not
shown). Infected non-engrafted NOD-scid IL2rc
null mice showed no
signs of illness. In a small group of mice, no significant differences in
platelet counts were detected in DENV-2 infected mice (9216179
10
3/mm
3; n=6) compared to mock infected mice (12986428
10
3/mm
3; n=3) during acute infection (days 5–8). Visible signs of
rash were detected in more than 30% of engrafted infected mice.
These data indicate that several infected engrafted mice exhibited
clinical features of human dengue illness although these features
were not consistently observed.
Figure 2. Bone marrow cells are susceptible to DENV-2 infection. Bone marrow cells (2610
6) from engrafted NOD-scid IL2rc
null mice were
infected (m.o.i.=2) in vitro with DENV-2 for 48 hrs. (A) Gating strategy used to identify cells with low and high side scatter. (B) Cells within the hCD45
+
cells in gate 1 were further analyzed for viral antigen using the 3H5 mAb in uninfected and infected bone marrow cells. (C) Summary of DENV antigen
expression in hCD45
+ cells after in vitro infection with DENV-NGC. Values represent frequencies of hCD45
+3H5
+ cells within the respective gates.
Median values are denoted by horizontal lines. Immunoperoxidase staining was performed to detect viral antigen in (D) DENV-2 infected bone
marrow cells and (E) uninfected bone marrow cells using the 3H5 antibody. (F) Persistently infected Raji cells (positive control) and (G) uninfected Raji
cells (negative control) were used to assess the specificity of staining.
doi:10.1371/journal.pone.0007251.g002
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To determine whether viral antigen was expressed following in
vivo infection, we assessed the distribution of DENV in multiple
organs including the spleen and bone marrow by multiparametric
flow cytometry. We utilized the DENV-2-specific mAb 3H5
directed against the envelope protein as well as the mAb 7E11
directed against the nonstructural protein NS1 of DENV-2, to
detect DENV antigen in NOD-scid IL2rc
null mice 3–7 days after in
vivo infection. The specificity of staining was confirmed using
DENV-specific mAbs on cells from mock infected mice and
control isotype antibodies on cells from infected mice (Fig. S1).
Data from multiple experiments are summarized in Fig. 3.
Splenocytes and bone marrow cells from mice infected 3 days
prior with DENV-2 had the highest frequencies of hCD45
+
antigen-positive cells using the 3H5 mAb with lower frequencies of
hCD45
+ antigen-positive cells detected in mice studied 5 or 7 days
post infection (Fig. 3A and B). Frequencies of hCD45
+ antigen-
positive cells were similar using the 7E11 antibody and reflected
the results we obtained with the 3H5 antibody in a subset of mice
tested (Fig. 3C and D). Frequencies of mCD45
+ antigen positive
cells in the spleens and bone marrow of infected mice at early time
points using the 3H5 antibody ranged from 0.1–1% (n=9) which
were in the range detected in mock infected mice with the
exception of 1 animal which had 3.3% mCD45
+3H5
+ cells.
Similarly, frequencies of mCD45
+7E11
+ cells ranged from 0–0.7%
(n=9) with frequencies in the spleens of 2 animals at 1.7 and
2.6%. Our data indicate that both structural and non-structural
DENV proteins could be detected predominantly in hCD45
+ cells
following in vivo infection of engrafted mice.
Assessment of viral loads in target organs of infected
mice
We further assessed the presence of DENV in the target organs
of infected mice. Fig. 4A demonstrates the detection of DENV
RNA by RT-PCR in the livers of 2 mice 7 days after s.c. infection
with DENV-2 while no RNA was detected in the livers of mock
infected mice. Data from multiple experiments are summarized in
Table 1. Virus was detected in greater than 50% of mice between
3 and 15 days post infection by the s.c. route. Mice infected by the
i.p. route had a similar pattern of distribution throughout the body
with virus being detected at early time points, although fewer mice
were positive for dengue RNA by RT-PCR (Table 1). In non-
Figure 3. Expression of viral antigen in target tissues of mice 3–7 days after in vivo infection. Spleen and bone marrow cells were
isolated from mice infected by the s.c. or i.p. route (n=17) with DENV or mock infected (n=5) mice 3–7 days post infection. Splenocytes and bone
marrow cells were assessed for the expression of the envelope protein of DENV-2 using the zenon conjugated 3H5 mAb (A and B) or a non structural
protein 1 of DENV-2 using the zenon conjugated 7E11 mAb (C and D). Data shown are frequencies of 3H5
+, 7E11
+ or ctrl Ab
+ cells within the human
CD45
+ lymphocyte gate.
doi:10.1371/journal.pone.0007251.g003
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null mice infected with DENV-2, no virus
was detected in any of the organs at any time point (Table 1). Our
data indicate that productive infection was detected only in
engrafted mice. Infection by the s.c. route resulted in greater
infection compared to infection by the i.p. route.
Based on a quantitative PCR assay which has detection limit of
1000 RNA copies per PCR reaction viral titers detected in the
spleens of mice early after infection (days 2–7) ranged from
1.1610
3 to 4.3610
5 copies/mg RNA (n=6 mice). In the liver, viral
titers ranged from 10
4 to 10
9 viral genome copies/mg RNA. RNA
quality was assessed by measuring copies of a housekeeping gene
b-actin in liver tissue. Normalized viral RNA copies relative to b-
actin levels are shown in Fig. 4B.
To confirm that the virus detected in organs of mice was due to
replicating infectious virus, we passaged liver lysates from DENV-2
infectedmiceonC6/36cellsanddetecteda5logincreaseofDENV-
2 genome copies in the supernatants of C6/36 cells by Q-PCR (data
not shown) at 5 and 10 days post infection. These data demonstrate
that infected NOD-scid IL2rc
null mice contained infectious DENV in
the liver known to be a target of infection in humans.
Antibody responses to DENV in engrafted NOD-scid
IL2rc
null mice
We assessed the generation of DENV-2-specific antibodies in
the sera of infected engrafted NOD-scid IL2rc
null mice by sandwich
ELISA. Significant levels of DENV-2 E-specific IgM antibodies
were detected in the sera of approximately 70% (13/19) infected
engrafted mice at early time points (5–7 days after infection) while
50% mice (7/15) were seropositive between days 10–15. Sera
obtained from mice prior to infection, mock infected mice and
infected non-engrafted mice at different time points were at
background levels (Fig. 5). A cohort of mice (n=8) was bled at 1, 2
and 3 weeks after infection with DENV-2 NGC. The highest IgM
response was detected at 1 week after infection in all mice tested
(Fig. 5) while DENV-specific IgM were at background values in
the sera of mice obtained 3 weeks after infection (data not shown).
Sera from mice with high DENV-specific IgM responses at 1 week
had no responses to an unrelated protein (data not shown). We
observed very low IgG responses (and only in a minority of mice
studied) even at later time points (4–6 weeks). These results suggest
Figure 4. Detection of dengue viral RNA in infected engrafted
NOD-scid IL2rc
null mice. (A) RNA was extracted from the livers of two
infected and two mock infected mice by the s.c. route. RNA was also
extracted from DENV-2 NGC and used as a positive control. Viral RNA
was amplified using Lanciotti primers as described in Materials and
Methods. (B) Normalized viral RNA levels on a subset of liver samples
that were positive by RT-PCR.
doi:10.1371/journal.pone.0007251.g004
Table 1. Detection of DENV in organs of infected NOD-scid IL2rc
null mice.
Reconstitution Route Day post infection Serum Spleen Bone marrow Liver
Yes s.c. Day 3 n.d.
** 0/2 0/2 0/2
Day 5 1/1 3/4 1/4 2/2
Day 7 10/13 5/8 5/8 6/8
Day 10 0/3 0/4 1/4 3/4
Day 13–16 14/17
* 0/6 0/6 4/9
*
Day 24–26 12/12 1/1 n.d. 3/3
Yes i.p. Day 3 3/5 1/4 2/4 n.d.
Day 5 n.d. 2/4 0/3 0/1
Day 7 1/7 2/6 1/6 n.d.
Day 10 0/1 1/2 0/2 1/1
Day 15 n.d. 0/3 0/3 0/1
No s.c. Day 3 0/2 0/2 0/2 0/2
Day 7 0/4 0/4 0/4 0/4
Day 15 0/3 0/3 0/3 0/3
Engrafted (n.28 s.c.; n=19 i.p.) or non-engrafted (n=9) NOD-scid IL2rc
null mice were inoculated with 1610
6 PFU DENV-2 NGC strain. Mice were sacrificed at different
time-points as indicated above and different organs were collected. RNA was isolated from the serum, bone marrow, spleen and liver and subjected to one-step RT-PCR
as described in Materials and Methods. Values represent the number of mice that were positive by PCR in the various organs tested.
*3 out of 17 mice and
* 3 out of 9 that were positive by PCR were administered 10 mg recombinant human BLyS 3 days prior to and 3 days after infection.
**n.d. = not determined.
doi:10.1371/journal.pone.0007251.t001
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null mice are capable of
generating human DENV-specific IgM antibodies.
Human T cell responses in NOD-scid IL2rc
null mice
Human T cell responses were not analyzed in humanized
BALB/c-RAG2
2/2cc
2/2 and NOD-scid-humanized mouse mod-
els used previously to study DENV infection [16–18]. We assessed
DENV-specific T cell immune responses to an inactivated DENV-
2 antigen used routinely in our laboratory to assess DENV-specific
human CD4
+ T cell responses by intracellular IFN-c staining
using the gating strategy shown in Fig. S2. As shown in Fig. 6A,
3.1% of human CD4
+ cells (upper right quadrant) produced IFN-c
in response to DENV-2 antigen while 0.5% human CD4+ cells
produced IFN-c to the control vero antigen. Responses of
splenocytes from the same mouse to a mitogen, PMA+ionomycin
resulted in down regulation of CD4 and indicated that
approximately 6% hCD45
+ cells secreted IFN-c.
At 1 (panel B) or 2 (panel C) weeks after infection, splenocytes
from infected mice had significantly higher frequencies of human
CD45
+ cells (n=14 mice), human CD4
+ cells (n=6 at week 1 and
n=14 at week 2) and human CD8 (n=9 at week 1 and n=10 at
week 2) T cells that produced IFN-c in response to stimulation with
DENV-2 antigen compared to the control antigen (Fig. 6B and C).
Splenocytes from uninfected engrafted mice had low frequencies of
human CD45
+ cells that produced IFN-c in response to DENV-2
antigen (1.260.9%) or the control antigen (0.660.3%). These
results indicate that human T cells in infected NOD-scid IL2rc
null
mice were capable of eliciting DENV-specific IFN-c responses.
Cytokine responses to HLA A2 restricted dengue virus-
specific peptides in human cord blood engrafted NOD-
scid HHD Tg(HLA-A2) mice
In order to determine whether CD8 T cells in humanized mice
are able to respond to A2 restricted virus-specific peptides
previously identified in humans, we assessed IFN-c responses in
NOD-scid IL2rc
null mice that were engrafted with HLA A2 cord
blood cells. We did not detect any significant peptide-specific IFN-
c responses in splenocytes from infected NOD-scid IL2rc
null mice to
3 HLA A2 restricted dengue-specific epitopes (data not shown).
We considered the possibility that inadequate education of human
T cells in the murine thymus microenvironment in these mice
might result in suboptimal T cell responses. We speculated that
NOD-scid IL2rc
null mice engineered to express HLA A2 might
support more effective human T cell education intrathymically on
human HLA A2 thus allowing for more robust human CD8 T
cell responses. We developed NOD-scid IL2rc
null Tg(HLA-A2/
Hub2M) mice that express human HLA A2 on mouse cells and
assessed T cell responses in mice that were infected with DENV-2.
Splenocytes obtained from mice 7 days after infection with
DENV-2 were stimulated with 3 HLA-A2 restricted peptides
NS4b 2353(111–119), NS4b 2423(181–189), and NS4a 2148(56–64)
identified in our laboratory [25]. We detected significant
frequencies of antigen-specific T cells that responded to ex vivo
stimulation with all three peptides by secreting IFN-c, TNF-a and
IL-2 (Figure 7A). A summary of CD3
+ CD8
+ IFN-c T cell
responses obtained from splenocytes of infected mice is shown in
Fig. 7B. Greater than 60% of mice had significant responses to all
three peptides. The results were obtained in 3 independent cohorts
of humanized mice reconstituted with cells from 3 different HLA-
A2
+ cord blood cells. Data in Fig. 7C suggest that T cell responses
in immunized mice were polyfunctional since cells that secreted
two cytokines (IFN-c
+TNF-a
+, IFN-c
+IL-2
+ and TNF-a
+IL-2
+)
were detected in response to peptide stimulation. Together, our
data indicate that humanized NOD-scid IL2rc
null Tg(HLA-A2/
Hub2M) mice are able to elicit T cell responses to known HLA A2
restricted dengue virus-specific CD8 T cell epitopes.
Discussion
The major objective of this study was to evaluate humanized
NOD-scid IL2rc
null mice as a small animal model for the study of
human DENV infection. Using a low dose of a laboratory strain of
DENV, our results indicate that NOD-scid IL2rc
null mice engrafted
with human hematopoietic stem cells are permissive to DENV
infection and generate DENV-specific human immune responses.
We identified human CD45
+ cells that were targets of DENV
infection following in vitro and in vivo infection. To our
knowledge, we are the first to demonstrate infection of human
cells and assess the generation of DENV-specific human T cell
responses in a humanized mouse model.
Our in vitro studies with clinical and laboratory passaged
DENV strains demonstrate that human CD45
+ cells in the bone
marrow of engrafted NOD-scid IL2rc
null mice are differentially
infected with multiple serotype-2 DENV strains. We and others
have observed varying degrees of infectivity following in vitro
infection of human primary cells and cell lines with clinical and
laboratory passaged strains of DENV-2 [26,27]. The vast majority
of infected cells detected were human CD45
+CD19
2 cells and
preliminary data suggest that CD11c
+ dendritic cell precursors in
the bone marrow of NOD-scid IL2rc
null mice may harbor DENV
antigen (data not shown). Although some studies have identified B
cells as an important target for DENV infection in humans, most
data have pointed to infection of monocytes and possibly dendritic
cells in vivo [15,28–30]. Further studies using different serotypes
and strains of DENV are required to identify predominant targets
of infection after in vitro infection.
Bente and Mota et al recently reported that NOD-scid mice
engrafted with human CD34
+ stem cells were susceptible to
Figure 5. Detection of IgM-specific antibodies in the sera of
infected engrafted NOD-scid IL2rc
null mice. Sera were obtained
from DENV-infected engrafted (n=8 at prebleed; n=19 at 1 week;
n=15 at 2 weeks), non-engrafted (n=8) and mock infected (n=6) NOD-
scid IL2rc
null mice. IgM antibodies against DENV-2 E protein were
detected by ELISA. Open circles represent OD values obtained from sera
of mice obtained at a single time point. Closed connected circles
represent values obtained from sera of the same mice that were bled at
1 and 2 weeks after infection with DENV-2 NGC. Open triangles
represent values obtained from mock infected mice. The Wilcoxin
signed rank test was used to assess significance.
doi:10.1371/journal.pone.0007251.g005
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Infected mice showed typical signs of dengue infection, including
fever, rash, weight loss and thrombocytopenia. We did not
consistently see any of these signs in our model using the
laboratory passaged DENV-2 NGC, although several infected
mice did show significant weight loss and had ruffled fur. We
performed limited studies with the same Thai isolate of DENV-2
used by Bente et al and obtained similar results to those seen with
DENV-2 NGC (data not shown). A possible explanation for
differences between our studies and others may include varying
strains of humanized mice used for the experiments. The NOD-
scid mice used by Bente et al do not generate human T or B cell
responses which may have influenced the ability of DENV to
replicate in target tissues. Since cord blood samples from several
different donors were used for reconstitution it may account for
differing susceptibilities of mature human cells to DENV infection
in NOD-scid IL2rc
null mice, which could contribute to the lack of
consistent findings of dengue disease in our mice.
We performed most of our experiments using a single
immunization with a prototype laboratory adapted strain
DENV-2 NGC. The NGC strain of DENV was originally serially
passaged in mouse brains and later extensively passaged in cell
culture for use by many laboratories [31]. We have not detected
any neurological symptoms in engrafted mice after infection with
DENV-2 NGC. Additionally, no virus was detected in any organs
of infected non-engrafted mice suggesting that the engrafted
human cells were necessary for in vivo replication of this mouse
adapted neurovirulent strain of virus and that the symptoms of
dengue disease that we have observed in humanized mice is not
likely due to replication in neuronal sites.
Detection of DENV RNA at multiple late time points post
infection in organs known to be targets of infection in humans is
encouraging and suggests that DENV-2 replicates within human
cells of infected mice. Detection of the NS1 protein in
predominantly hCD45
+ cells using the mAb 7E11 suggests that
the viral RNA detected by RT-PCR is due to replication of DENV
within cells in humanized NOD-scid IL2rc
null mice, consistent with
productive infection. Confirmation of the ability of infectious virus
in liver lysates from infected mice to infect C6/36 cells further
validates our PCR and flow cytometry results. Further studies will
be needed to compare DENV tropism in this mouse model to
those in humans.
Similar to results by Kuruvilla et al, we have detected virus in
the sera (data not shown) and livers of mice that persisted for .20
days in our initial studies in a subset of NOD-scid IL2rc
null mice.
Mice with high viremia lost weight and appeared sick while mice
with low level or intermittent viremia had less appreciable weight
loss. We are still unclear why some mice harbor DENV several
weeks after infection. We speculate that the low IgG responses and
inefficient human T cells generated in NOD-scid IL2rc
null mice
Figure 6. Human T cells secrete IFN-c in response to dengue antigen stimulation. (A) Splenocytes from a mouse immunized two weeks
prior with DENV-2 NGC were stimulated with an inactivated DENV-2 Ag, control vero antigen, PMA (0.1 mg/ml) + ionomycin (1 mg/ml) or media. Data
shown are frequencies of human CD4
+ T cells that produced IFN-c in response to stimulation. (B and C) Frequencies of human CD45+, hCD4
+ and
hCD8
+ IFN-c secreting cells from DENV-2 infected engrafted NOD- scid IL2rc
null mice at 1 or 2 weeks post infection. The Wilcoxin signed rank test was
used to assess significance.
doi:10.1371/journal.pone.0007251.g006
Humanized Mice and Dengue
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more recent studies with NOD-scid IL2rc
null Tg(HLA-A2/Hub2M)
mice however, we have not detected any virus in the sera of mice
at 2 or more weeks post infection. The results with humanized A2
transgenic NOD-scid IL2rc
null mice are highly encouraging and
must be considered when evaluating varying humanized models as
suitable animal models to assess dengue infection and immunity
since infectious virus is cleared in approximately 2 weeks after
natural infection in humans.
We detected DENV-2-specific IgM antibodies in the sera of
mice 5–14 days after infection indicating that these mice are able
to generate antibody responses against DENV. However, as
reported by others [21], we detected little or no DENV-specific
IgG (data not shown) suggesting that very low levels of class
switching occurred in these mice. Variable and low IgG responses
in these mice might be due to a lack of species cross-reactive
cytokines in the xenogenic environment [32,33]. We treated a
small group of mice with B Lymphocyte Stimulatory Factor
(BLyS), a factor known to promote human B cell survival [34,35]
and B cell engraftment in NOD-scid IL2rc
null mice (unpublished
observations). Sera from BLyS-treated DENV-infected mice did
not show substantially higher DENV-specific IgM or IgG
responses (data not shown). Kuruvilla et al demonstrated high
levels of DENV-specific IgM and IgG in stem cell engrafted RAG-
hu mice several weeks post infection [18]. However, only RAG-hu
mice that were immunized with a pool of four different strains of
DENV-2 generated a strong antibody response while mice
infected with individual strains of DENV-2 had very low levels
of dengue-specific antibodies. The basis for the difference in
response to the mixture of viruses was not determined. Antibody
responses in our model might be enhanced by using a pool of
different DENV-2 strains as done by Kuruvilla et al or by
increasing the viral inoculum. However neither strategy mimics
the natural course of DENV infection.
One major difference between our study and previous studies of
DENV infection in humanized mouse models is our demonstration
Figure 7. A2 restricted human T cell responses in NOD-scid HHD Tg(HLA–A2)mice. Splenocytes from infected NOD-scid HHD Tg(HLA–A2)mice
were stimulated for 6 hrs with 10 mg/ml of NS4b 2353(111–119), NS4b 2423(181–189), and NS4a 2148(56–64). A) Representative dot plots indicating the
frequencies (upper right quadrant) of IFN-c+, TNF-a
+ and IL-2
+ T cells by intracellular cytokine staining. B) Frequencies of hCD45
+CD3
+CD8
+ IFN-c
+
secreting T cells in splenocytes of infected NOD-scid IL2rc
null Tg(HLA–A2/Hub2M) and C) Representative plots demonstrating double cytokine
secretion of antigen-specific T cells in response to stimulation with 10 mg/ml of NS4a 2148(56–64).
doi:10.1371/journal.pone.0007251.g007
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antigen and virus-specific peptides. Most of the mice immunized by
either the i.p. or s.c. route had significant DENV-specific IFN-c
responses to the inactivated antigen with low intensity staining at 1–
2 weeks post infection. Several studies have reported the important
role of IFN-c in the clearance of DENV infection [13,36,37]. It
remains unclear how the human T cells generated in NOD-scid
IL2rc
null mice are effectively educated. While mature human T cells
could develop by extrathymic education and selection [24,33],
presumably most of their education occurs in the murine thymus.
Melkus et al were able to overcome this problem by using NOD-scid
mice implanted with human fetal liver and thymic tissues to
measure human EBV-specific immune responses [38].
Our data using NOD-scid IL2rc
null Tg(HLA–A2/Hub2M) mice
are very encouraging and indicate that expression of human HLA
molecules allow for better education of dengue-specific human T
cells in humanized mice. As far as we know, we are the first to
demonstrate A2 restricted peptide-specific responses in humanized
mice. The ability of T cells to respond to ex vivo peptide stimulation
by secreting multiple cytokines including IFN-c, TNF-a and IL-2
demonstrate the polyfunctionality of T cells in NOD-scid IL2rc
null
Tg(HLA-A2/Hub2M) mice. The frequency of cells that respond to
the 3 A2 restricted peptides by secreting IFN-c in splenocytes of
humanized mice (0.1–2.8% of total CD3
+CD8
+ T cells) is in line
with frequencies detected in human PBMC of DENV immune
donors (0.1–0.68% of total CD3
+CD8
+ T cells) [25]. These
preliminary studies suggest that NOD-scid IL2rc
null Tg(HLA-A2/
Hub2M)mice can be used effectively to assess T cell responses to
virus-specific peptides identified in humans. Further experiments
will need to be performed to assess the frequency and function of
dengue-specific T cells during acute infection, in memory as well as
following sequential heterologous dengue virus infections.
There are still some limitations in immunodeficient IL2rc
null
humanized mouse models including the requirement of human
specific molecules for optimal function of the human immune
system and issues of remaining innate immunity that present
obstacles to human hematopoietic stem cell engraftment [39]. In
addition, optimal conditions to ensure reliable human T and B cell
engraftment will likely involve for example the use of neonatal
rather than adult mice for engraftment and transgenic expression
of select cytokines. Overcoming these limitations should be
achievable in the future and will allow investigators to better
recapitulate immune responses observed in immunocompetent
individuals in humanized mouse models.
In summary, we have characterized a humanized mouse model
with functional DENV-specific adaptive immune responses. The
virologic and immunologic data presented set the stage for
investigating both host and virus-specific mechanisms that control
primary and sequential DENV infections. Since prior immunity is a
major risk factor to developing DHF, these mice could potentially be
used to study the role of cross-reactive sub-neutralizing antibodies
and T cells during sequential DENV infections. Understanding the
contribution of hostcomponentsto severedenguediseasewillleadto
the development of effective therapeutics and vaccines.
Materials and Methods
Ethics Statement
All experiments were performed in accordance with guidelines
of the Institutional Animal Care and Use Committee of the
University of Massachusetts Medical School and the recommen-
dations in the Guide for the Care and Use of Laboratory Animals (Institute
of Laboratory Animal Resources, National Research Council,
National Academy of Sciences, 1996).
Immunodeficient Mice
NOD.Cg-Prkdc
scidIl2rg
tm1Wjll/SzJ mice (hereafter termed: NOD-
scid IL2rc
null) and NOD.Cg-Prkdc
scidIl2rg
tm1Wjll Tg(HLA-A2/H2-D/
b2M)1Dvs/Sz (hereafter termed NOD-scid IL2rc
null Tg(HLA-A2/
Hub2M) mice were bred at the Jackson Laboratory and
subsequently maintained in the animal facilities at the University
of Massachusetts Medical School [20]. The HLA-A2/Hub2M
transgene encodes a human b2-microglubulin (b2M) covalently
linked to the MHC class 1, alpha1 and alpha2 binding domains of
the human HLA-A2.1 gene and the alpha3, cytoplasmic and
transmembrane domains of the murine H2-D
b[40,41].
Transplantation of human umbilical cord blood-derived
hematopoietic stem cells in NOD-scid IL2rc
null mice
Umbilical cord blood (UCB) was obtained in accordance with
the Committee for the Protection of Human Subjects in Research
guidelines of the University of Massachusetts Medical School. It
was provided by the medical staff of the UMass Memorial
Umbilical Cord Blood Donation Program. The program educates
and consents mothers regarding UCB collection for research and
public banking and performs collections at the time of delivery.
Human umbilical cord blood (UCB) samples were depleted of red
blood cells by double density Percoll gradient (1.05/1.077) and
depleted of T cells using Stem Cell Technologies’ (Vancouver, BC)
StemSep human CD3+ depletion cocktail. CD34+ cells in the T
cell-depleted UCB preparation were enumerated by flow cytom-
etry and the sample was resuspended in phosphate buffered saline
(PBS) for injection. Young adult mice 6–10 weeks of age of either
sex received 240 cGy whole body irradiation (WBI) prior to
intravenous delivery of 3610
4 CD34+ UCB in a volume of 1.0 ml
via the lateral tail vein. Human cells were allowed to engraft and to
generate an immune system in recipient mice for at least 12 weeks,
at which time human hematolymphoid engraftment was validated
by flow cytometry on peripheral blood. Successfully engrafted
mice were then randomized based on engraftment for use in
experiments.
Viruses
Dengue virus serotype-2 strains New Guinea C (DENV-2
NGC), 16681 (DENV-2-16681) and a low passage DENV-2 Thai
isolate were propagated in C6/36 cells cultured in RPMI 1640
(Invitrogen, Grand Island, NY) containing 5% heat-inactivated
fetal calf serum (FCS; Gibco) at 28uC as previously described [42].
The low passage clinical strain was isolated from the sera of a
patient on Study Day 1 (strain K0005/94, passage 2) with a
diagnosis of DHF-grade 2 in a prospective study of dengue
infections in Thailand [43,44]. Virus titers were determined by
plaque-forming assay on Vero cells.
DENV infection of humanized NOD-scid IL2rc
null mice
Groups of engrafted and non-engrafted NOD-scid IL2rc
null mice
were inoculated s.c. or i.p. with approximately 10
6 PFU of DENV-
2. Additional groups of engrafted mice were injected with control
C6/36 cell culture supernatant. Weights of mice and signs of
illness were monitored every other day for 30 days. Organs
(spleen, liver and bone marrow) were surgically removed from
mice euthanized at different times post infection. A portion of the
spleen and liver, sera and bone marrow cells were immediately
frozen at 280uC for RNA analysis. The remaining portion of the
spleen, bone marrow and PBMC were depleted of RBCs using
RBC lysis buffer (SIGMA, St. Louis, MO) and processed to make
single cell suspensions for T cell assays and to identify virus-
infected cells.
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Sera, liver, bone marrow and spleen were tested for the
presence of DENV RNA by RT-PCR. RNA from different organs
was subjected to reverse-transcription and amplification using a
Qiagen One-Step RT-PCR Kit (Qiagen) with DENV-2-specific
primers D1 and TS2 as described by Lanciotti et al [45].
Viral RNA copy numbers in different organs were measured by
using quantitative real-time RT-PCR based TaqMan system
(Applied Biosystems, Foster City, CA) [46]. The RNA was
subjected to reverse-transcription and amplification using a
TaqMan One-Step RT-PCR Master Mix Reagents Kit (PE
Biosystems) with DENV-2 consensus primers (forward, 59-
CAGATCTCTGATGAATAACCAACG-39, and reverse, 59CA-
TTCCAAGTGAGAATCTCTTTGTCA -39) and DENV-2 con-
sensus TaqMan probe (6FAM-59ATGCTGAAACGCGAGA-
GAAACCGC -39-TAMRA). Probed products were quantitatively
monitored by their fluorescence intensity with the ABI7300 Real-
Time PCR system (PE Biosystems). DENV-2 viral RNA was used
as control RNA for quantification. Viral RNA in different organs
was calculated based on the standard curve of control RNA. b-
actin primers were used to control for the quality of RNA (Applied
Biosystem, Foster City, CA) in the liver tissue. A ratio was
calculated by dividing the average Ct value obtained for all 17
samples by b-actin Ct values obtained for each sample. Ratios
ranged from 0.90–1.1 for all samples indicating uniform quality of
RNA in samples of liver tissue. Viral RNA copies were then
normalized for RNA loading using this ratio. All assays were
carried out in triplicate.
Identification of virus-infected cells by flow cytometry
Bone marrow cells from DENV-2 infected mice were infected
with different strains of DENV in vitro at an m.o.i. of 2 for 48 hrs.
For in vitro and in vivo infections, cell suspensions were washed
with FACS buffer (PBS with 2%FCS and 0.1% sodium azide) and
blocked with CD16/CD32 (Fc block 2.4G.2) mAb for 15 min at
4uC and then stained with APC-conjugated anti-human (h) CD45
(clone 2D1) and PECy7-conjugated anti-mouse (m) CD45 (clone
30-F11) for 30 min at 4uC (BD Biosciences). Cells were washed,
fixed and permeabilized for 20 min using Cytofix/CytoPerm (BD
Biosciences) and stained intracellularly for the presence of DENV-
2 using PE-zenon (Molecular Probes) conjugated 3H5 (DENV-2
envelope specific) or Pacific blue-zenon conjugated 7E11 (DENV-
2 NS1 specific) antibodies. All cell preparations were fixed with
Cytofix and analyzed on a FACSARIA flow cytometer (BD
Biosciences). FlowJo (TreeStar Inc. Ashland, OR.) version 7.1 was
used to analyze data.
Identification of virus-infected cells by
immunoperoxidase staining
Approximately 48 hrs after in vitro infection, 1610
5 cells were
spun onto cytospin slides for 3 min at 600 rpm and air dried. The
cells were fixed in cold methanol and then permeabilized with
0.1% TritonX-100 in PBS. Endogeneous peroxidase activity was
blocked by treating cells with 3% hydrogen peroxide. The cells
were further processed using the VECTASTAIN ABC Kit
(VECTOR) and the DENV-2-specific monoclonal antibody 3H5
(1:200). Color was developed by treating cells with the DAB kit
(VECTOR) for 1–10 min.
DENV isolation from organs of infected humanized NOD-
scid IL2rc
null mice
Frozen liver tissue was processed in small volume (1–1.5 ml) of
complete media using a 70 micron cell strainer. The lysate was
centrifuged at 2000 rpm for 15 min and 1 ml of the supernatant
was collected. 100 ml of the supernatant from livers of 3 infected
mice were used to infect a monolayer of C6/36 cells in 6 well
plates for 90 min. Monolayers were next washed with media and
replaced with 1.5 mls of fresh media. At different time points (1 hr,
5 days and 10 days) supernatants were collected and frozen at
280c. RNA was extracted from the C6/36 supernatant using
QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA). RNA was
amplified by Q-PCR as stated above.
Detection of IFN-c production by intracellular staining
Approximately 0.5–1610
6 spleen cells from DENV-infected
mice were incubated with either an inactivated lysate of DENV-2
infected Vero cells (1:40), control Vero cell lysate (1:40), 10 mg/ml
of the indicated peptide, RPMI 1640 medium (GIBCO) or
phorbol myristic acid (0.1 mg/ml) + ionomycin (1 mg/ml). Vero
cell lysates were prepared as previously described [42]. Golgi plug
(BD Biosciences) was added to each of the above samples and
incubated at 37uC. For experiments that used the inactivated
dengue antigen, splenocytes were stimulated for 18 hrs while
peptide stimulations were performed for 6 hrs. Cells were washed
with FACS buffer, blocked with Fc block (2.4G2) for 10 min and
then surface stained with FITC-hCD45 (clone 2D1), PECy7-
mCD45 (clone 30-F11), Alexa-700-hCD3 (clone UCHT1), PE-
hCD8 (clone H1T8a) and Pacific Blue-hCD4 (clone RPAT4)
antibodies for 20 min at room temperature. Cells were washed
with FACS buffer, then permeabilized using Cytofix/Cytoperm
buffer (BD Biosciences) and stained with hIFN-c (clone B27),
TNF-a (clone Mab11) and IL-2 (clone MQ1-17H12) antibody for
20 min at room temperature. In some experiments the viability
marker LIVE/DEADH Aqua (Molecular Probes) was added to
exclude dead cells. All cell preparations were fixed with Cytofix
(BD Biosciences). Significant responses were considered to be 2
standard deviations above frequencies associated with cells
stimulated with media.
Enzyme-linked immunosorbent assay
Levels of DENV-2 envelope (E) protein-specific antibody in the
serum of DENV-infected, uninfected engrafted and non-engrafted
mice were determined using a standard Enzyme-linked immuno-
sorbent assay (ELISA). 96-well microplates were coated overnight
with 100 ng/well of DENV-2 E protein (Hawaii Biotech). The
plates were blocked with 1% bovine serum albumin for 90 min
and a 1:20 dilution of sera diluted with PBS was added to the wells
for one hour. After washing the plates, horseradish peroxidase-
labeled goat anti-human IgM (Bethyl Laboratories INC. Mon-
tgomery, Texas; Catalog no. A80–100P) was added as the
secondary antibody. TMB Solution (SIGMA-ALDRICH Inc.,
St. Louis, MO) was used as the substrate. The enzyme reaction
was stopped by addition of 1M HCL and the plates were read at
450 nm. All assays were carried out in duplicate or triplicate.
Statistical Analysis
Data are expressed as mean value 6 standard deviation (SD).
Significant differences between groups were determined by the
Wilcoxin signed rank test. P values ,0.05 were considered
significant.
Supporting Information
Figure S1 Detection of dengue antigen after in vivo infection.
Five days after a s.c. infection with DENV-2 NGC or C6/36
supernatant, hCD45+ and mCD45+ cells from the bone marrow
were assessed for dengue antigen expression. The specificity of
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PLoS ONE | www.plosone.org 10 October 2009 | Volume 4 | Issue 10 | e7251staining was confirmed using mAbs 3H5 and 7E11 (top panel) and
isotype control antibodies (middle panel) on bone marrow cells
from infected mice. 3H5 and 7E11 staining on mock infected bone
marrow cells (lower panel) is also shown. Values represent
frequencies of antigen-positive cells within the hCD45+ or
mCD45+ gate.
Found at: doi:10.1371/journal.pone.0007251.s001 (1.26 MB TIF)
Figure S2 Gating strategy to identify hCD4+ and hCD8+ cells.
Initial gating strategy to identify cells in the lymphocyte gate was
based on forward and side scatter profiles. hCD45+ cells were next
selected for using markers directed against mouse and human
CD45. Viable hCD45+ were gated on by exclusion of the viability
marker LIVE DEAD AQUA. T cells were next selected for by
identifying CD3+ cells within the lymphocyte gate and further
subsets delineated using antibodies directed against hCD4 and
hCD8.
Found at: doi:10.1371/journal.pone.0007251.s002 (0.74 MB TIF)
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